Anavex Life Sciences Highlights New Scientific Findings on Shared Biology between Autism and Alzheimer's disease

Published: 2026-04-15 09:42:09 ET AVXL

Published on 04/15/2026 at 09:42 am EDT

NEW YORK - Anavex Life Sciences Corp. ('Anavex' or the 'Company') (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced new findings on the shared biology between autism spectrum disorder (ASD) and Alzheimer's disease (AD), a core area of Anavex' development plans with its autophagy enhancing orally administered blarcamesine.

Key Highlights

Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD) and Alzheimer's disease (AD), including shared disruptions in autophagy.

Epidemiological data show that autistic adults may be diagnosed with Alzheimer's and related dementias at rates up to 8 times higher than the general population, with onset occurring years or decades earlier than typical.

Converging human genetic evidence links numerous high-confidence ASD risk genes - including TSC1/TSC2, PTEN, SHANK3, and FMRP - to impaired cellular autophagy, establishing autophagy dysfunction as a shared molecular substrate across genetically diverse forms of ASD.

Synaptic dysfunction in ASD is now understood to arise, in substantial part, from a failure of autophagy-dependent synaptic pruning - causing an excess of poorly regulated synaptic connections and disrupted excitatory-inhibitory balance in neural circuits.

The brain's extracellular matrix (ECM) is pathologically altered in ASD and is bidirectionally coupled to autophagy.

Restoration of autophagy impairment, now emerging as a central shared pathway in both ASD and AD, is precisely the biological system targeted by blarcamesine through its activation of SIGMAR1.

Blarcamesine has demonstrated restoration of autophagy through SIGMAR1 activation in preclinical models and has shown clinical effects in Phase IIb/III trials in early Alzheimer's disease, Phase II/III in Rett syndrome (a neurodevelopmental disorder caused by MECP2 mutation), and Phase II in Parkinson's disease dementia.

Collectively, these data provide a scientific basis for advancing blarcamesine into pivotal clinical studies, subject to further evaluation and regulatory considerations.

Reframing Brain Disorders: Converging Pathways in Neurodevelopment and Neurodegeneration

For decades, autism and Alzheimer's disease were treated as conditions on opposite ends of the lifespan - one affecting brain development in early childhood, the other driving decline in old age. New research is adding a critical new twist. A landmark April 2025 study published in JAMA analyzed Medicare and Medicaid records covering more than 114,000 autistic adults and found that dementia prevalence among this population was dramatically elevated compared to the general population.-1 A separate recent 2026 paper in Frontiers in Neuroscience identified convergent disruptions in two critical systems shared by both conditions: The autophagy network and the synaptic regulation machinery.

Autophagy is the cell's natural process for clearing misfolded proteins, damaged organelles, lipids, and other cellular waste. In autism, excess synaptic connections form which are not properly pruned during development. In Alzheimer's disease, impaired autophagy, worsened by ApoE4 lipoproteins, allows toxic protein aggregates - including amyloid-beta and fibrillary tau - to accumulate unchecked. Both conditions, in essence, share a common driver of disease pathogenesis: A failure of the brain's housekeeping system.

Synaptic Dysfunction in ASD: When the Brain's Pruning Mechanism Fails

The human brain is sculpted by a process of exuberant synapse formation followed by selective elimination - synaptic pruning - that removes excess connections and renders neural circuits fully functional. Autophagy is a core cellular mechanism enabling this pruning. A landmark Neuron study-3 found excess dendritic spines in postmortem ASD cortical tissue compared to controls - direct evidence of failed pruning correlating with impaired autophagy. Blocking neural autophagy genetically reproduced core ASD features: Excess synapse density, impaired social behavior, and repetitive behaviors; restoring autophagy normalized both synaptic architecture and behavior. Microglia, the brain's resident immune cells, depend equally on autophagy for synapse elimination.4 The downstream consequence of both failures is a disruption of excitatory-inhibitory balance - a core pathobiological signature of ASD.56

The Genetic Architecture of ASD Converges on Autophagy

ASD is genetically heterogeneous, yet genome analyses repeatedly converge on a common theme: Mutations and copy-number variants in genes whose protein products regulate autophagy. Among the most studied are mutations in TSC1/TSC2 and PTEN genes, whose loss of function suppresses autophagy and is associated with high rates of ASD alongside epilepsy and intellectual disability.7 Fragile-X syndrome - the most common inherited cause of intellectual disability and autism - likewise involves reduced autophagic flux in hippocampal neurons, with activation of autophagy rescuing aberrant spine morphology, synaptic plasticity, and cognition in preclinical models.5 SHANK3 mutations further alter autophagy-dependent protein homeostasis at the synapse.8 Whole-exome sequencing has additionally identified copy-number variants in core autophagy genes in sporadic ASD cases.? This genetic convergence is not coincidental; it is pathobiologically instructive.

The Brain'Datexx15 April 2026/